- Home
- NVCR vs WRBY Comparison
NVCR vs WRBY Comparison
Compare NVCR & WRBY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVCR
- WRBY
- Stock Information
- Founded
- NVCR 2000
- WRBY 2010
- Country
- NVCR Jersey
- WRBY United States
- Employees
- NVCR N/A
- WRBY N/A
- Industry
- NVCR Medical/Dental Instruments
- WRBY Ophthalmic Goods
- Sector
- NVCR Health Care
- WRBY Health Care
- Exchange
- NVCR Nasdaq
- WRBY Nasdaq
- Market Cap
- NVCR 1.8B
- WRBY 1.9B
- IPO Year
- NVCR 2015
- WRBY 2021
- Fundamental
- Price
- NVCR $17.49
- WRBY $17.23
- Analyst Decision
- NVCR Buy
- WRBY Buy
- Analyst Count
- NVCR 5
- WRBY 8
- Target Price
- NVCR $26.60
- WRBY $16.88
- AVG Volume (30 Days)
- NVCR 1.3M
- WRBY 1.4M
- Earning Date
- NVCR 10-30-2024
- WRBY 11-07-2024
- Dividend Yield
- NVCR N/A
- WRBY N/A
- EPS Growth
- NVCR N/A
- WRBY N/A
- EPS
- NVCR N/A
- WRBY N/A
- Revenue
- NVCR $549,964,000.00
- WRBY $719,929,000.00
- Revenue This Year
- NVCR $16.23
- WRBY $15.94
- Revenue Next Year
- NVCR $6.09
- WRBY $13.07
- P/E Ratio
- NVCR N/A
- WRBY N/A
- Revenue Growth
- NVCR 8.33
- WRBY 13.67
- 52 Week Low
- NVCR $10.87
- WRBY $9.83
- 52 Week High
- NVCR $24.74
- WRBY $18.37
- Technical
- Relative Strength Index (RSI)
- NVCR 43.24
- WRBY 57.79
- Support Level
- NVCR $15.61
- WRBY $16.71
- Resistance Level
- NVCR $17.31
- WRBY $17.86
- Average True Range (ATR)
- NVCR 1.29
- WRBY 0.66
- MACD
- NVCR 0.05
- WRBY 0.01
- Stochastic Oscillator
- NVCR 11.59
- WRBY 62.77
About NVCR NovoCure Limited
NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.
About WRBY Warby Parker Inc.
Warby Parker Inc is engaged in designing and developing designer prescription glasses and contacts, and providing the facility of eye exams and vision tests. The company predominantly derives revenue from the sales of eyewear products, optical services, and accessories. The firm sells products and services through its stores, website, and mobile apps. Revenue generated from eyewear products includes the sales of prescription and non-prescription optical glasses and sunglasses, contact lenses, eyewear accessories, and expedited shipping charges.